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Abstract
Although considered to be a rare infection, mucormycosis (zygomycosis) has emerged as the second most common invasive mould
infection. Despite the advent of newer antifungal agents, mortality rate of mucormycosis remains exceedingly high. Successful management
of mucormycosis requires early diagnosis, reversal of underlying predisposing risk factors, surgical debridement and prompt administration
of active antifungal agents. However, mucormycosis is not always amenable to cure. There are challenging obstacles that lead to difﬁculties
in management of amphotericin B. These include unique host-based risk factors for mucormycosis, the fungus’ resistance to innate host
defences and distinctive features of its immunopathogenesis, such as extensive angioinvasion, increased virulence and use of chelators by the
fungus as siderophores. In addition to these obstacles, the difﬁculties in early diagnosis, including nonspeciﬁc clinical manifestations, lack of
serological methods, as well limitations of culture and molecular methods, lead to delay in initiation of antifungal therapy. Finally, the
variability of susceptibility to amphotericin B and resistance to most other conventional antifungal agents leads to major limitations in
successful treatment of this devastating infection.
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Introduction
Invasive fungal infections are important causes of morbidity
and mortality especially in immunocompromised patients.
While Candida spp., Aspergillus spp. and Cryptococcus neoformans
are responsible for the preponderance of invasive fungal
infections, other less common fungal pathogens account for a
signiﬁcant proportion of morbidity and mortality [1]. Among
these pathogens with worldwide distribution and increasing
frequency are Zygomycetes causing mucormycosis (previously
called zygomycosis) [2]. Mucormycosis is caused by fungi of the
order Mucorales and the family Mucoraceae [3]. Rhizopus,
Mucor, and Lichtheimia (formerly Absidia) are the most common
genera that cause mucormycosis, accounting for 70–80% of all
cases, whereas Cunninghamella, Apophysomyces, Saksenaea,
Rhizomucor, Cokeromyces, Actinomucor and Syncephalastrum are
responsible for <1–5% of reported cases [4].
A feature that is characteristic for Mucorales among other
ﬁlamentous fungi is that they cause disproportionately serious
infections with exceedingly high morbidity and mortality in
relatively immunocompetent individuals [5]. This may be
particularly observed in patients with diabetes mellitus, neo-
nates, as well as those with wounds caused by surgery, trauma
and burns. Despite aggressive surgical intervention and inten-
sive antifungal treatment, mortality of mucormycosis is high,
ranging from 50–100% depending on the disease form [3,5,6].
By comparison, mortality rates for candidiasis and aspergillosis
range from 20–50% and 35–45%, respectively [7–9].
Successful management of mucormycosis requires early
diagnosis, reversal of underlying predisposing risk factors,
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12466
surgical debridement and prompt administration of ampho-
tericin B [10]. However, despite these measures, mucormy-
cosis is not always amenable to cure. We will discuss, in this
article, the challenging obstacles that lead to difﬁculties in
management of mucormycosis (Table 1).
Patient Population at Risk for Mucormycosis
Mucormycosis is an infection affecting all ages, from premature
neonates to elderly people with varying types of underlying
conditions [5,11–13]. While the incidence rates of invasive
mucormycosis in these diverse patient groups have not been
well studied, the current data demonstrate increased incidence
in a wide range of speciﬁc immunocompromised patient
groups [2,5,11].
In the most contemporary epidemiologic study of muco-
rmycosis in Europe, the most common underlying diseases
were haematological malignancies (44%) followed by diabetes
mellitus (17%) and trauma (17%) [2]. Data from a global fungal
infection registry that included patients from central Europe
and Asia demonstrated that malignancy (63%), diabetes (17%)
and solid organ transplantation (10%) predominated as
underlying conditions for mucormycosis [11].
A comprehensive review of 929 reported cases showed
that the most common underlying condition were diabetes
(36%), followed by malignancy (17%), solid organ transplanta-
tion (7%), deferoxamine therapy (6%), injection drug use (5%)
and bone marrow transplantation (5%). In addition, the
patients’ underlying conditions were shown to be related with
the pattern of infection, in that, patients with malignancy had
more likely pulmonary infection; whereas, patients with
diabetes mellitus had sino-orbital and rhinocerebral disease
[5,14]. This relationship would be, in all probability, a reﬂection
of the host’s immune function along with other pathologi-
cal-anatomical factors [5].
However, it has also been postulated that the differences in
disease pattern may reﬂect the diversity between developed
and developing countries from where the cases were reported
[15]. Speciﬁcally, in developed countries, most patients with
mucormycosis are those with diabetes and haematological
malignancies [6], while in developing countries those with
uncontrolled diabetes and trauma predominate [16,17]. Nota-
bly, there is a relatively large proportion (c. 14% in children and
19% in adults) with no apparent immunocompromising con-
ditions at the time of infection [5,18]. Within France, traumatic
wounds in immunocompetent and immunocompromised
patients comprise a distinct population [14].
The differences in the population at risk for mucormycosis
depicted by the current studies could be explained by the
period effect, publication bias or the contribution of different
investigational centres in each study. However, it is charac-
teristic that while other ﬁlamentous fungi affect more classi-
cally deﬁned immunocompromised hosts, such as those with
malignancies under chemotherapy, transplant recipients or
inherited immunodeﬁciencies, mucormycosis can cause seri-
ous infections in relatively immunocompetent hosts, such as
those with diabetes mellitus, on deferoxamine therapy,
injection drug users and with no apparent immune defect
other than a traumatic injury [5,18]. Correspondingly, taking
also into account the ubiquitous nature of Mucorales, deﬁning
a speciﬁc population at risk for mucormycosis in order to
target it is a challenging problem as ‘candidate-patients’
represent a quite heterogeneous group.
Distinctive Features of the
Immunopathogenesis of Mucormycosis
Medically important members of the order Mucorales share
many features with other ﬁlamentous fungi such as portals of
the host for infection (airways and disrupted mucocutaneous
barriers), the main lines of innate host defences (phagocytes,
speciﬁc ligands in fungal spores such as pathogen-associated
molecular patterns (PAMPs) and immune cells such as Toll-like
receptors (TLRs)), as well as histopathological and clinical
features [19,20]. However, Rhizopus oryzae and other selected
Mucorales possess unique virulence characteristics and exert
distinctive host–pathogen interactions compared to other
fungi facilitating, thus, host evasion and disease progression
[21].
TABLE 1. Possible reasons for difﬁculty to treat
mucormycosis
Variable underlying conditions of mucormycosis
Haematological malignancies
Diabetes
Solid organ transplantation
Haematopoietic stem cell transplantation
Injection drug use
Neonates
Trauma
Burns
Normal host
Deferoxamine therapy
Distinctive features of immunopathogenesis
Extensive angioinvasion
Increased virulence (exerted by some species, see text)
Use of chelators by fungus as siderophores
Difﬁculties in diagnosis
Non-speciﬁc clinical manifestations
Lack of validated or standardized serological methods
Difﬁculties in culturing organism
Limited availability of validated and standardized molecular methods
Limitations of antifungal therapy
Late or no diagnosis antemortem
Elevated MICs of amphotericin B
Higher MICs of Cunninghamella to amphotericin B
Triazole-speciﬁc variability of susceptibility
Species-speciﬁc variability of susceptibility to triazoles
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There are several lines of in vitro evidence showing that
R. oryzae and other members of the Mucorales have reduced
susceptibility to innate host defence as compared to other
more common fungi, such as Aspergillus fumigatus or Candida
albicans [22,23]. Moreover, differential interspecies suscepti-
bility patterns to host responses exist within the order
Mucorales [24–26]. Namely, members of the genus Rhizopus
suffer less hyphal damage and stimulate an impaired oxidative
burst in human phagocytes as compared to Lichtheimia (Absidia)
spp. [24], and Cunninghamella bertholletiae shows, in vitro,
increased resistance to phagocyte-induced hyphal damage and,
in vivo, increased virulence in an experimental neutropenic
pulmonary mucormycosis model in comparison with Rhizopus
spp. [25,26]. In agreement are the results of the Drosophila
melanogaster host model that simulates important aspects of
mucormycosis in humans. In contrast to other fungi, species
within the order Mucorales rapidly infect and kill D. melanog-
aster wild-ﬂies, and their pathogenicity is linked with impaired
phagocytic cell activity and hyphal damage compared with
those of A. fumigatus [27]. These experimental ﬁndings are
collectively consistent with epidemiological data and clinical
experience showing greater prevalence of Rhizopus spp.
compared to Lichtheimia corymbifera in immunocompromised
patients [3,28–30] and increased mortality in patients with
C. bertholletiae infection [4,5].
While the exact mechanisms underlying such variable
responses against Zygomycetes have not yet been elucidated,
the increased virulence exerted by some species has been
associated with the induction of a more pronounced proin-
ﬂammatory response by selected species [25,31]. It was
postulated that differences in cell-wall constituents and ligands
may lead to variable recognition of fungal cell wall recognition
patterns by TLR and dectin receptors with consequent
downstream altered expression of certain stimulatory mole-
cules like chemokines and cytokines [24,31]. Indeed, the
D. melanogaster model demonstrated the importance of fungal
recognition for infection development showing that Toll-deﬁ-
cient ﬂies exhibit increased susceptibility to infections caused
by the Mucorales [27]. Whole-genome expression proﬁling in
wild-type ﬂies after infection with Mucorales vs. A. fumigatus
revealed that genes acting on pathogen recognition, immune
defence, stress response, detoxiﬁcation, steroid metabolism or
tissue repair are differentially regulated by these two fungal
pathogens [27].
One of the critical characteristics in mucormycosis patho-
genicity is the extensive angioinvasion that results in vessel
thrombosis and tissue necrosis [6,32]. This angioinvasion leads
to haematogenous dissemination of the organism to target
organs, while ischaemic necrosis of the infected tissue can
prevent leucocyte and antifungal agent penetration to the foci
of infection [21]. R. oryzae was used as a model system in
understanding the basis of fungal pathogenicity. Sequencing the
genome of a pathogenic R. oryzae strain there was evidence
that the entire genome had been duplicated and retained two
copies of three extremely sophisticated systems involved in
energy generation and utilization. This gene duplication has led
to the development of gene families related to fungal virulence,
fungal cell wall synthesis enzymes and signal transduction,
which may contribute to the invasive nature of R. oryzae [33].
The seminal clinical observations that patients with diabetic
ketoacidosis as well as patients receiving dialysis who are
treated with iron chelator deferoxamine are characteristically
susceptible to mucormycosis highlights the central role of host
iron in the pathogenesis of mucormycosis [21,34]. In proof of
principle in vitro studies, it was shown that Rhizopus spp. can
accumulate 8- and 40-fold greater amounts of iron supplied by
deferoxamine than can A. fumigatus and C. albicans, respec-
tively [35]. Similarly, data from animal models showed that
administration of deferoxamine or free ions reduced survival
of animals infected with Rhizopus spp. but not C. albicans [36–
38]. Deferoxamine per se is not the pathogenetic factor for
infection, but Rhizopus spp. utilize deferoxamine as a sidero-
phore to supply previously unavailable iron to the fungus [6].
However, not all Zygomycetes have the same susceptibility to
iron chelators [39].
Among the classic enhancers of mucormycosis pathogenic-
ity in humans is corticosteroid immunosuppressive therapy
and diabetes mellitus, which seem to impair the ability of
macrophages to prevent germination of sporangiospores
[40,41]. Neutropenia encountered in patients with haemato-
logical malignancies and in the pre-engraftment stage of HSCT
is a major contribution to the pathogenesis of mucormycosis
[20,21,23–26]. Further contributing to the pathogenesis of
mucormycosis is the presence of a receptor–ligand interaction
between endothelial cell surfaces and Rhizopus oryzae [21].
More recently, it was found that exposure of Mucorales to
voriconazole selectively enhanced their virulence [42]. Up to
date, a number of potential virulence factors including
mycotoxins and lytic enzymes excreted by Rhizopus spp. have
been proposed; however, their contribution to Zygomycetes
pathogenicity needs to be further elucidated [21].
Difﬁculties in Mucormycosis Diagnosis
Early and accurate diagnosis is, a priori, the most critical aspect
for improved outcome of mucormycosis given the limited
therapeutic options available, which frequently involve disﬁg-
uring and debilitating surgeries. However, many suspected
mucormycosis cases ranging from 4 to >90% are not
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conﬁrmed until post-mortem examination [2,43–45]. The
establishment of a deﬁnite diagnosis is hampered by a variety
of factors including non-speciﬁc clinical presentation of muco-
rmycosis as well as the various drawbacks of the currently
implemented diagnostic means.
There are some clinical manifestations such as diplopia,
necrotic naso-sinus eschars, pleuritic pain, necrotic cutaneous
lesions that, in the predisposed host, carry a potentially high
predictive value [15,43]. These clinical manifestations are
discussed in greater depth elsewhere. Nevertheless, these
manifestations are nonspeciﬁc and their differential diagnosis
includes a range of infections caused by angioinvasive patho-
gens, including Aspergillus spp., Fusarium spp., Scedosporium spp.
and Pseudomonas aeruginosa; therefore, a high index of
suspicion and prompt identiﬁcation of host predisposing
factors are required for early recognition of mucormycosis.
Cultural isolation and identiﬁcation of the fungus to the
genus or species level is of epidemiological, prognostic and
therapeutic importance [4,26,43]. The cultural isolation yield
ranges from 50 to 71%, while it was documented that it was
signiﬁcantly improved over time [2,5]. However, recovery of
Mucorales from specimens in clinical microbiology laboratories
is challenging. Performing invasive procedures to obtain the
necessary material especially in severely ill patients with
thrombocytopenia or coagulopathy may be a daunting and
perilous task. The hyphae of Mucorales may be difﬁcult to
observe on wet mounts and need special chitin-binding stains
with a ﬂuorescent microscope or may not be abundant so as
to be seen. Moreover, tissue handling aggressive tissue grinding
or homogenization may destroy the coenocytic hyphae
[43,46]. While Mucorales are usually morphologically distinc-
tive from other ﬁlamentous fungi, in some cases where
antifungal therapy has commenced before biopsy, morpholog-
ical features may be atypical, reducing the ability to differen-
tiate Mucorales from other ﬁlamentous fungi [43].
Currently, there are no readily available nonculture meth-
ods, such as measurement of biochemical or serological
biomarkers, to facilitate the diagnosis of invasive mucormy-
cosis. By comparison, circulating mannan antigen and
(1?3)-b-D-glucan are used for diagnosis of invasive candidi-
asis, while galactomannan measured in serum and bronchoal-
veolar lavage (BAL) ﬂuid is useful in the diagnosis of invasive
aspergillosis.
Molecular identiﬁcation is feasible and holds promise for
early and accurate diagnosis of mucormycosis. Most studies
have evaluated ribosomal targets (18S, 28S and internal
transcribed spacer (ITS)) or other DNA targets (the high-afﬁn-
ity iron permease I gene FTRI or cytochrome b) that allow
species identiﬁcation of Zygomycetes from cultures [47].
Molecular methods also play a role in formalin-ﬁxed, paraf-
ﬁn-embedded biopsy samples, which, on many occasions,
constitute the only material available for use for diagnosis in
the clinical setting.
The greater challenge for early diagnosis of mucormycosis is
to develop molecular systems for identiﬁcation of amplicon
from blood or BAL ﬂuid in patients with invasive pulmonary
mucormycosis. One of the ﬁrst laboratory animal studies to
demonstrate circulating species-speciﬁc amplicon from plasma
and BAL ﬂuid in experimental invasive pulmonary mucormy-
cosis found sensitivities of 67% and 100% with a high degree of
speciﬁcity [48]. Other studies from experimental animal
models as well as case reports from patients further demon-
strate the feasibility in identifying Mucorales such as C. bert-
holletiae, Rhizomucor pusillus, R. microsporus, L. corymbifera and
Saksenaea vasiformis from tissue and cultures [48–55]. In these
cases molecular approaches are mainly based on PCR assays;
however, the performance of these techniques can become
compromised, as formalin ﬁxation is associated with DNA
damage. Currently, molecular diagnostics for mucormycosis is
not widely available; its use is compromised by limited
sensitivity, time to detection and ability to provide rapid
results. Collectively, while molecular diagnosis of mucormy-
cosis is feasible, several areas, such as DNA extraction
methodology, identiﬁcation of informative DNA targets, a
validated sequence database, a broader spectrum of primers,
as well as systematic validation and standardization of assays in
human specimens warrant improvement [43,56].
A protocol of the European Confederation of Medical
Mycology (ECMM)—International Society for Human and
Animal Mycology (ISHAM) Zygomycosis Working Group will
be systematically addressing these needs for advancing the
development of antigenic, biochemical and molecular assays
for diagnosis of invasive pulmonary mucormycosis. The three
objectives of development of a predictive risk model, an
archive of human specimens and an educational effort are
aimed at advancing the early diagnosis of invasive mucormy-
cosis.
Diagnostic imaging and especially CT scan is an invaluable
tool to aid in early diagnosis of invasive infections in
immunocompromised hosts. Nevertheless, radiological fea-
tures are not pathognomonic of mucormycosis while their
absence cannot exclude this infection [57]. Many lesions, such
as nodules, halo sign, reverse halo sign, cavities, wedge-shaped
and pleural effusions, characteristically occur in pulmonary
mucormycosis as well as other angioinvasive organisms like
Aspergillus spp., Scedosporium spp., Fusarium spp. and P. aeru-
ginosa [43,57].
Early and accurate diagnosis of mucormycosis is an area of
critical importance and until newer molecular diagnostic
techniques and biomarkers become available, diagnosis will
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be based on prompt recognition of risk factors, clinical
manifestations and radiological ﬁndings and with conformation
by culture and biopsy [43].
Difﬁculties in Treatment of Mucormycosis
The advent of newer antifungal agents signiﬁcantly improved
the prognosis in immunocompromised patients with invasive
fungal infections. However, in the case of mucormycosis, the
invasive nature of the disease leads to an overall mortality
exceeding 50%, while on many occasions, antifungal therapy
alone is rarely effective resulting in 100% mortality particularly
for patients with disseminated disease [2,5,14] (Fig. 1).
Various Mucorales organisms have differential responses to
antifungal agents. For example, R. oryzae tends to exhibit in
vitro resistance to posaconazole; Mucor circinelloides shows
greater susceptibility to posaconazole, and Cunninghamella
tends to have higher MICs to amphotericin B [43]. In addition,
the same species have variable response to the same antifungal
class, for example R. oryzae has a variable response to different
triazoles, including lack of activity of voriconazole as compared
to relatively good activity of posaconazole. The recent
sequencing of R. oryzae revealed that this strain is genetically
equipped for adaptation to hostile environments such as the
effects of antifungal agents. It has been advocated that the
variable responses of R. oryzae to voriconazole, itraconazole
and posaconazole are possibly due to the increased copy
number and divergence of duplicated ERG11 (the principal
gene target for the triazoles) [33]. Consequently, the MICs for
itraconazole and posaconazole are 4–8 dilutions higher for
R. oryzae than those for A. fumigatus, and fungicidal activity is
not achieved over a range of safely achievable drug concen-
trations [58–60]. The frequent breakthrough R. oryzae infec-
tions occurring in patients receiving voriconazole indicate that
this antifungal agent is ineffective against R. oryzae [61,62]. This
adaptive ability of R. oryzae may result in higher potential for
development of resistance during long-term triazole therapy
than A. fumigatus [63].
Amphotericin B is considered the ﬁrst line therapy for
mucormycosis. However, there are many lingering use prob-
lems to resolve, including the optimal dosage and timing for
treatment initiation for each site of infection. Many clinicians
who treat mucormycosis in an effort to control the infection
use maximum tolerance doses of liposomal amphotericin B
with a risk for nephrotoxicity. Studies from animal models
showed that higher amphotericin B tissue concentration may
be required for effective treatment of mucormycosis as
compared to aspergillosis [64–66], while a phase II clinical
trial of high-dose liposomal amphotericin B (10 mg/kg/day, IV)
in mucormycosis treatment has been recently completed
pending the efﬁcacy results (http://clinicaltrials.gov/show/
NCT00467883).
The impact of prompt amphotericin B-based treatment on
the outcome of patients with mucormycosis has been
determined by a retrospective study [67]. Chamilos et al.
[67] demonstrated that delayed amphotericin B-based therapy
resulted in a two-fold increase in mortality in patients with
haematological malignancy and mucormycosis compared with
early treatment (83% vs. 49%). Furthermore, delayed treat-
ment of invasive mucormycosis was an independent predictor
of poor outcome in multivariate analysis (odds ratio, 8 (95%
conﬁdence interval, 1.7–38.2); p 0.008). Given that Mucorales
grow rapidly in vivo, there is a ‘window of opportunity’, which
is much shorter than that of aspergillosis, where effective
treatment should be initiated before extensive angioinvasion
and dissemination occur [63]. Notably, while in vitro echino-
candins demonstrate virtually no activity against Mucorales, in
vivo, they are modestly effective [63]. Notably, at higher
doses, echinocandins have attenuated activity compared with
lower doses possibly reﬂecting upregulation of homeostatic
cell-wall responses in the fungi that ‘rescue’ the fungus from
the effects of echinocandins through compensatory increase
in chitin synthesis [68,69]. In this regard, treatment options
with predictable and favourable pharmacokinetics, such as
lipid formulations of amphotericin B with echinocandin
provide a reasonable rationale for phase III randomized,
double-blinded, placebo-controlled trials [63]. However,
more work on the safety, tolerability, efﬁcacy, pharmacoki-
netics and pharmacodynamics is needed in a wider range of
animal models of invasive pulmonary mucormycosis to assure
that this hypothesis is tenable before embarking on a phase III
trial.
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FIG. 1. Treatment modalities against mucormycosis. PMN, polymor-
phonuclear neutrophils; MNC, monocytes; GM-CSF, Granulo-
cyte-Macrophage-Colony-Stimulating Factor; IFN-c, Interferon-c.
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Conclusions
Mucormycosis has a worse outcome than other invasive fungal
infections such as candidiasis or aspergillosis. The higher
degree of difﬁculty to cure this devastating infection is related
to differences in host–fungus interactions, and pathogenetic
mechanisms, as well as greater difﬁculties in early diagnosis
when the ‘window’ of successful treatment is higher, and wider
inadequacies of therapeutic options. Further advances in
understanding host defence, developing newer diagnostic tools
and creating better therapeutic interventions may improve
outcome of this devastating disease.
Acknowledgements
Dr Walsh is a Scholar of the Henry Schueler Foundation in
Mucormycosis and of the Sharp Family Foundation in Pediatric
Infectious Diseases.
Transparency Declaration
Dr Katragkou does not disclose any potential conﬂict of
interests. Dr Walsh receives research grants for experimental
and clinical antimicrobial pharmacotherapeutics from Astellas,
ContraFect, Trius, Cubist, Merck, Medimmune, Novartis and
Pﬁzer. He has served as consultant to Astellas, ContraFect,
Cubist, Drais, Gilead, iCo, Novartis, Methylgene, Pﬁzer,
SigmaTau and Trius. Dr Roilides has served on the speaker’s
bureau of Gilead, Cephalon, Pﬁzer, Wyeth, Schering, Merck,
Aventis, Astellas, Elpen; has served as consultant to Schering,
Gilead, Astellas, Pﬁzer; and has received grant support made to
his institution from Pﬁzer, Gilead, Enzon, Schering, Wyeth.
References
1. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E.
Infections due to emerging and uncommon medically important fungal
pathogens. Clin Microbiol Infect 2004; 10 (suppl 1): 48–66.
2. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of
230 cases accrued by the registry of the European Confederation of
Medical Mycology (ECMM) working group on zygomycosis between
2005 and 2007. Clin Microbiol Infect 2011; 17: 1859–1867.
3. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease.
Clin Microbiol Rev 2000; 13: 236–301.
4. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by
unusual mucormycetes, non-rhizopus, -mucor, and -lichtheimia species.
Clin Microbiol Rev 2011; 24: 411–445.
5. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and
outcome of zygomycosis: a review of 929 reported cases. Clin Infect
Dis 2005; 41: 634–653.
6. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on
mucormycosis: pathophysiology, presentation, and management. Clin
Microbiol Rev 2005; 18: 556–569.
7. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of
candidemia in 2019 patients: data from the prospective antifungal
therapy alliance registry. Clin Infect Dis 2009; 48: 1695–1703.
8. Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis:
a multicenter retrospective analysis of 139 contemporary cases.
Pediatrics 2008; 121: e1286–e1294.
9. Steinbach WJ, Marr KA, Anaissie EJ et al. Clinical epidemiology of 960
patients with invasive aspergillosis from the path alliance registry. J
Infect 2012; 65: 453–464.
10. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS.
Recent advances in the management of mucormycosis: from bench to
bedside. Clin Infect Dis 2009; 48: 1743–1751.
11. Ruping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive
zygomycosis from a global clinical registry. J Antimicrob Chemother 2010;
65: 296–302.
12. Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and
children. Clin Microbiol Infect 2009; 15 (suppl 5): 50–54.
13. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK Jr, Walsh TJ.
Zygomycosis in neonates: an uncommon but life-threatening infection.
Am J Perinatol 2009; 26: 565–573.
14. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of
mucormycosis in france: the retrozygo study (2005–2007). Clin Infect
Dis 2012; 54 (suppl 1): S35–S43.
15. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoy-
iannis DP. Epidemiology and clinical manifestations of mucormycosis.
Clin Infect Dis 2012; 54 (suppl 1): S23–S34.
16. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a
review of the clinical manifestations, diagnosis and treatment. Clin
Microbiol Infect 2004; 10 (suppl 1): 31–47.
17. Chakrabarti A, Das A, Mandal J et al. The rising trend of invasive
zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol
2006; 44: 335–342.
18. Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a
systematic review and analysis of reported cases. Pediatr Infect Dis J
2007; 26: 723–727.
19. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction
of fungal pathogens with pattern recognition receptors in the
activation and modulation of host defence. Clin Microbiol Infect 2006;
12: 404–409.
20. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against
zygomycetes. Clin Infect Dis 2012; 54 (suppl 1): S61–S66.
21. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of
mucormycosis. Clin Infect Dis 2012; 54 (suppl 1): S16–S22.
22. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP.
Zygomycetes hyphae trigger an early, robust proinﬂammatory
response in human polymorphonuclear neutrophils through toll-like
receptor 2 induction but display relative resistance to oxidative
damage. Antimicrob Agents Chemother 2008; 52: 722–724.
23. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte
colony-stimulating factor administered in vivo augments neutro-
phil-mediated activity against opportunistic fungal pathogens. J Infect
Dis 1997; 175: 1012–1015.
24. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM,
Walsh TJ. Interferon gamma and granulocyte-macrophage colony-
stimulating factor augment the activity of polymorphonuclear leuko-
cytes against medically important zygomycetes. J Infect Dis 2005; 191:
1180–1187.
25. Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella
bertholletiae exhibits increased resistance to human neutrophils with or
without antifungal agents as compared to Rhizopus spp. Med Mycol
2010; 48: 720–724.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 74–81
CMI Katragkou et al. Difﬁculties in treating mucormycosis 79
26. Petraitis V, Petraitiene R, Antachopoulos C et al. Increased virulence
of Cunninghamella bertholletiae in experimental pulmonary mucormy-
cosis: correlation with circulating molecular biomarkers, sporangios-
pore germination and hyphal metabolism. Med Mycol 2013; 51: 72–
82.
27. Chamilos G, Lewis RE, Hu J et al. Drosophila melanogaster as a model
host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad
Sci USA 2008; 105: 9367–9372.
28. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North
Am 2002; 16: 895–914, vi.
29. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in
the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–
856.
30. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and
outcome of mould infections in hematopoietic stem cell transplant
recipients. Clin Infect Dis 2002; 34: 909–917.
31. Warris A, Netea MG, Verweij PE et al. Cytokine responses and
regulation of interferon-gamma release by human mononuclear cells to
Aspergillus fumigatus and other ﬁlamentous fungi. Med Mycol 2005; 43:
613–621.
32. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A
clinicopathological study of pulmonary mucormycosis in cancer
patients: extensive angioinvasion but limited inﬂammatory response. J
Infect 2009; 59: 134–138.
33. Ma LJ, Ibrahim AS, Skory C et al. Genomic analysis of the basal lineage
fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet
2009; 5: e1000549.
34. Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey C,
Segaert MF. The role of desferrioxamine in dialysis-associated muco-
rmycosis: report of three cases and review of the literature. Clin
Nephrol 1988; 29: 261–266.
35. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during
deferoxamine therapy is a siderophore-mediated infection. In vitro and
in vivo animal studies. J Clin Invest 1993; 91: 1979–1986.
36. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR.
Deferoxamine augments growth and pathogenicity of Rhizopus, while
hydroxypyridinone chelators have no effect. Kidney Int 1994; 45: 667–
671.
37. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine
and from ferrirhizoferrin by germinating spores of Rhizopus microsporus.
Biochem Pharmacol 1994; 47: 1843–1850.
38. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and
iron on experimental mucormycosis (zygomycosis). Kidney Int 1989; 36:
1061–1068.
39. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis
DP. Activity of deferasirox in mucorales: inﬂuences of species and
exogenous iron. Antimicrob Agents Chemother 2011; 55: 411–413.
40. Shoham S, Levitz SM. The immune response to fungal infections. Br J
Haematol 2005; 129: 569–582.
41. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar
macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.
J Infect Dis 1984; 150: 752–760.
42. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G,
Kontoyiannis DP. Increased virulence of Zygomycetes organisms
following exposure to voriconazole: a study involving ﬂy and murine
models of zygomycosis. J Infect Dis 2009; 199: 1399–1406.
43. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis
DP. Early clinical and laboratory diagnosis of invasive pulmonary,
extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin
Infect Dis 2012; 54 (suppl 1): S55–S60.
44. Pagano L, Ofﬁdani M, Fianchi L et al. Mucormycosis in hematologic
patients. Haematologica 2004; 89: 207–214.
45. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomy-
cosis: report of four cases and review. Rev Infect Dis 1989; 11: 741–754.
46. Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues
using calcoﬂuor white and ﬂuorescence microscopy. Arch Pathol Lab
Med 1984; 108: 616–618.
47. Dannaoui E. Molecular tools for identiﬁcation of zygomycetes and the
diagnosis of zygomycosis. Clin Microbiol Infect 2009; 15 (suppl 5): 66–70.
48. Kasai M, Harrington SM, Francesconi A et al. Detection of a molecular
biomarker for zygomycetes by quantitative PCR assays of plasma,
bronchoalveolar lavage, and lung tissue in a rabbit model of experi-
mental pulmonary zygomycosis. J Clin Microbiol 2008; 46: 3690–3702.
49. Schwarz P, Bretagne S, Gantier JC et al. Molecular identiﬁcation of
zygomycetes from culture and experimentally infected tissues. J Clin
Microbiol 2006; 44: 340–349.
50. Machouart M, Larche J, Burton K et al. Genetic identiﬁcation of the
main opportunistic mucorales by pcr-restriction fragment length
polymorphism. J Clin Microbiol 2006; 44: 805–810.
51. Iwen PC, Freifeld AG, Sigler L, Tarantolo SR. Molecular identiﬁcation
of Rhizomucor pusillus as a cause of sinus-orbital zygomycosis in a
patient with acute myelogenous leukemia. J Clin Microbiol 2005; 43:
5819–5821.
52. Lechevalier P, Hermoso DG, Carol A et al. Molecular diagnosis of
Saksenaea vasiformis cutaneous infection after scorpion sting in an
immunocompetent adolescent. J Clin Microbiol 2008; 46: 3169–3172.
53. Kobayashi M, Togitani K, Machida H, Uemura Y, Ohtsuki Y, Taguchi H.
Molecular polymerase chain reaction diagnosis of pulmonary muco-
rmycosis caused by Cunninghamella bertholletiae. Respirology 2004; 9:
397–401.
54. Larche J, Machouart M, Burton K et al. Diagnosis of cutaneous
mucormycosis due to Rhizopus microsporus by an innovative
PCR-restriction fragment-length polymorphism method. Clin Infect
Dis 2005; 41: 1362–1365.
55. Dannaoui E, Schwarz P, Slany M et al. Molecular detection and
identiﬁcation of zygomycetes species from parafﬁn-embedded tissues
in a murine model of disseminated zygomycosis: a collaborative
european society of clinical microbiology and infectious diseases
(escmid) fungal infection study group (eﬁsg) evaluation. J Clin Microbiol
2010; 48: 2043–2046.
56. Balajee SA, Sigler L, Brandt ME. DNA and the classical way:
identiﬁcation of medically important molds in the 21st century. Med
Mycol 2007; 45: 475–490.
57. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The
diagnostic value of halo and reversed halo signs for invasive mold
infections in compromised hosts. Clin Infect Dis 2011; 52: 1144–1155.
58. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole,
ﬂuconazole, itraconazole, voriconazole, and amphotericin B against a
large collection of clinically important molds and yeasts. Antimicrob
Agents Chemother 2006; 50: 2009–2015.
59. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro
activities of posaconazole, itraconazole, voriconazole, amphotericin b,
and ﬂuconazole against 37 clinical isolates of zygomycetes. Antimicrob
Agents Chemother 2002; 46: 1581–1582.
60. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro
susceptibilities of zygomycetes to conventional and new antifungals. J
Antimicrob Chemother 2003; 51: 45–52.
61. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a
tertiary-care cancer center in the era of aspergillus-active antifungal
therapy: a case-control observational study of 27 recent cases. J Infect
Dis 2005; 191: 1350–1360.
62. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ
transplant recipients: a prospective, matched case-control study to
assess risks for disease and outcome. J Infect Dis 2009; 200: 1002–
1011.
63. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP,
Walsh TJ. How does antifungal pharmacology differ for mucormycosis
versus aspergillosis? Clin Infect Dis 2012; 54 (suppl 1): S67–S72.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 74–81
80 Clinical Microbiology and Infection, Volume 20 Supplement 6, June 2014 CMI
64. Ibrahim AS, Gebremariam T, Husseiny MI et al. Comparison of lipid
amphotericin B preparations in treating murine zygomycosis. Antimicrob
Agents Chemother 2008; 52: 1573–1576.
65. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP.
Comparative analysis of amphotericin B lipid complex and liposomal
amphotericin B kinetics of lung accumulation and fungal clearance in a
murine model of acute invasive pulmonary aspergillosis. Antimicrob
Agents Chemother 2007; 51: 1253–1258.
66. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP.
Comparative pharmacodynamics of amphotericin B lipid complex and
liposomal amphotericin B in a murine model of pulmonary mucormy-
cosis. Antimicrob Agents Chemother 2010; 54: 1298–1304.
67. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin
b-based frontline therapy signiﬁcantly increases mortality among
patients with hematologic malignancy who have zygomycosis. Clin
Infect Dis 2008; 47: 503–509.
68. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits
Rhizopus oryzae 1,3-beta-d-glucan synthase, lowers burden in brain
measured by quantitative PCR, and improves survival at a low but not a
high dose during murine disseminated zygomycosis. Antimicrob Agents
Chemother 2005; 49: 721–727.
69. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow
NA. Stimulation of chitin synthesis rescues Candida albicans from
echinocandins. PLoS Pathog 2008; 4: e1000040.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 74–81
CMI Katragkou et al. Difﬁculties in treating mucormycosis 81
